136 related articles for article (PubMed ID: 36622096)
1. Successful treatment of eosinophilic fasciitis with the anti-IL5 receptor monoclonal antibody benralizumab.
Rizzo C; La Barbera L; Camarda F; Destro Castaniti GM; Orlando E; Guggino G
Clin Exp Rheumatol; 2023 Mar; 41(3):763-764. PubMed ID: 36622096
[No Abstract] [Full Text] [Related]
2. Benralizumab in Real Life.
Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
[No Abstract] [Full Text] [Related]
3. Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.
Miyata Y; Inoue H; Homma T; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):346-348. PubMed ID: 33030432
[No Abstract] [Full Text] [Related]
4. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
5. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
6. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
8. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
10. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
11. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
Chica-Guzmán MV; Morillo-Guerrero R; Carrón-Herrero A; González-de-Olano D; Almonacid-Sánchez C
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
[No Abstract] [Full Text] [Related]
12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
13. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
15. Reverse butterfly pattern image with eosinophilia: Effective treatment with benralizumab-A case report.
Ben-David Y; Bentur L; Gur M; Ilivitzki A; Gut G; Toukan Y; Nir V; Shallufi G; Bar-Yoseph R
Pediatr Pulmonol; 2021 Aug; 56(8):2736-2739. PubMed ID: 34077999
[TBL] [Abstract][Full Text] [Related]
16. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
18. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
19. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
[No Abstract] [Full Text] [Related]
20. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]